Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Accumulated Expenses: 2009-2024

Historic Accumulated Expenses for Madrigal Pharmaceuticals (MDGL) over the last 12 years, with Dec 2024 value amounting to $124.7 million.

  • Madrigal Pharmaceuticals' Accumulated Expenses rose 163.64% to $345.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $345.4 million, marking a year-over-year increase of 163.64%. This contributed to the annual value of $124.7 million for FY2024, which is 38.58% up from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Accumulated Expenses of $124.7 million as of FY2024, which was up 38.58% from $90.0 million recorded in FY2023.
  • In the past 5 years, Madrigal Pharmaceuticals' Accumulated Expenses ranged from a high of $124.7 million in FY2024 and a low of $45.2 million during FY2020.
  • Moreover, its 3-year median value for Accumulated Expenses was $91.5 million (2022), whereas its average is $102.0 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 91.32% in 2020, then decreased by 1.62% in 2023.
  • Over the past 5 years, Madrigal Pharmaceuticals' Accumulated Expenses (Yearly) stood at $45.2 million in 2020, then grew by 21.73% to $55.0 million in 2021, then spiked by 66.15% to $91.5 million in 2022, then declined by 1.62% to $90.0 million in 2023, then spiked by 38.58% to $124.7 million in 2024.